PRCT's Adjusted EBITDA Loss Worsens Beyond Projections, Undermining 2026 Profitability Targets

What happened

PROCEPT BioRobotics has been navigating a commercial reset with targets for 27-33% revenue growth and 65% gross margin in 2026, aiming for positive adjusted EBITDA by Q4 2026. However, the company recently disclosed an adjusted EBITDA loss of $50.2 million, significantly exceeding the projected $35 million loss and triggering a 15% stock decline and a law firm investigation. This divergence highlights a critical failure in execution, contradicting management's assurances and raising doubts about the path to profitability. The DeepValue report emphasized risks like handpiece ASP sustainability and cash burn, which now appear more acute given the larger-than-expected loss. Consequently, investor trust in the commercial reset and management's credibility has eroded, threatening the core investment thesis based on margin inflection.

Implication

The immediate implication is heightened stock volatility and regulatory scrutiny, with the law firm investigation adding litigation risk that could distract management. Long-term, if PRCT fails to stabilize handpiece ASP and align shipments with procedures, the stock may trend toward the bear case value of $18, reflecting prolonged losses. Investors should closely monitor upcoming quarterly reports for signs of pricing discipline and cash burn trajectory, as deviations could necessitate further de-rating. This event underscores the fragility of the commercial reset, making it imperative to adjust position sizes to account for increased uncertainty and potential dilution risks. Overall, a more cautious stance is warranted until management demonstrates tangible progress toward the guided adjusted EBITDA inflection.

Thesis delta

The original thesis of a potential buy relied on PRCT hitting 2026 margin and revenue targets to re-rate the stock. The $50.2 million adjusted EBITDA loss versus a $35 million projection represents a material setback, shifting the thesis toward a more skeptical view that questions management's forecasting accuracy and execution capability. Investors should now demand concrete evidence of improvement in handpiece ASP and shipments-to-procedure normalization before considering entry, potentially revising the attractive entry point downward.